Skip to content
10-K

Annual Report

ALBIREO PHARMA, INC.

0001558370-22-002501

← back to feed
Filed
Mar 1, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2021 · Feb 22, 2022 19.36M sh
Shares Diluted FY 2021 · Dec 31, 2021 19.22M sh
Shares Diluted FY 2021 · Dec 31, 2020 15.98M sh
Stock Repurchased FY 2021 · Dec 31, 2021 $230K
Capex FY 2021 · Dec 31, 2021 $465K
Capex FY 2021 · Dec 31, 2020 $78K
Operating Cash Flow FY 2021 · Dec 31, 2021 −$107.56M
Operating Cash Flow FY 2021 · Dec 31, 2020 −$101.03M
Cash And Equivalents FY 2021 · Dec 31, 2021 $248.11M
Cash And Equivalents FY 2021 · Dec 31, 2020 $251.27M
Stockholders Equity FY 2021 · Dec 31, 2021 $175.61M
Stockholders Equity FY 2021 · Dec 31, 2020 $181.23M
Stockholders Equity FY 2021 · Dec 31, 2019 $93.16M
Current Liabilities FY 2021 · Dec 31, 2021 $45.35M
Current Liabilities FY 2021 · Dec 31, 2020 $25.28M
Total Liabilities FY 2021 · Dec 31, 2021 $126.44M
Total Liabilities FY 2021 · Dec 31, 2020 $104.38M
Current Assets FY 2021 · Dec 31, 2021 $268.93M
Current Assets FY 2021 · Dec 31, 2020 $261.87M
Total Assets FY 2021 · Dec 31, 2021 $302.05M
Total Assets FY 2021 · Dec 31, 2020 $285.61M
Eps Diluted FY 2021 · Dec 31, 2021 −$1.77
Eps Diluted FY 2021 · Dec 31, 2020 −$6.73
Eps Basic FY 2021 · Dec 31, 2021 −$1.77
Eps Basic FY 2021 · Dec 31, 2020 −$6.73
Sga Expense FY 2021 · Dec 31, 2021 $69.57M
Sga Expense FY 2021 · Dec 31, 2020 $42.45M
Rd Expense FY 2021 · Dec 31, 2021 $82.52M
Rd Expense FY 2021 · Dec 31, 2020 $76.78M
Net Income FY 2021 · Dec 31, 2021 −$34.03M
Net Income FY 2021 · Dec 31, 2020 −$107.63M
Operating Income FY 2021 · Dec 31, 2021 −$123.49M
Operating Income FY 2021 · Dec 31, 2020 −$96.27M
Gross Profit FY 2021 · Dec 31, 2021 $39.22M
Gross Profit FY 2021 · Dec 31, 2020 $8.31M
Cost Of Revenue FY 2021 · Dec 31, 2021 $1.36M
Revenue FY 2021 · Dec 31, 2021 $40.58M
Revenue FY 2021 · Dec 31, 2020 $8.31M